SCHEMBL25368915

SCHEMBL25368915

COc1cc(Cl)cc(NC(=O)c2csc(C(=O)Nc3cccc(NS(C)(=O)=O)c3)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.47
▸ NPC1 O15118 4/20 0.47
▸ KMT2A Q03164 5/20 0.47
▸ MEN1 O00255 4/20 0.47
▸ MAPT P10636 3/20 0.46
▸ MAPK1 P28482 3/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.44
▸ DHX9 Q08211 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ THRB P10828 1/20 0.43
▸ NLRP3 Q96P20 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543940 1.00 RAB9A (0.47) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL25368034 0.87 KMT2A (0.60) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL25351564 0.85 MEN1 (0.50) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL30535443 0.85 MEN1 (0.50) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL25368447 0.85 HPGD (0.51) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL30543904 0.83 DHX9 (0.50) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL25368623 0.83 DHX9 (0.50) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL30543946 0.82 DHX9 (0.53) RAB9AKMT2AMEN1MAPTMAPK1
SCHEMBL25368280 0.82 DHX9 (0.53) RAB9AKMT2AMEN1MAPTMAPK1
SCHEMBL25368096 0.81 RAB9A (0.53) RAB9ANPC1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B RAB9A 388/4885NPC1 2484/4885KMT2A 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback